NG BIOTECH

Executive Summary

NG Biotech is a French diagnostics company specializing in rapid tests for infectious diseases, with a particular focus on combating antimicrobial resistance (AMR). In February 2026, the company announced that the U.S. FDA granted Breakthrough Device Designation to two of its rapid tests targeting WHO-critical priority pathogens: one for a drug-resistant fungal threat and another for a drug-resistant bacterial threat. This designation underscores the urgent medical need for innovative diagnostics in the fight against AMR and provides NG Biotech with expedited development and regulatory review pathways. The tests, developed in partnership with undisclosed collaborators, aim to enable rapid, point-of-care identification of these dangerous pathogens, facilitating timely treatment and infection control. NG Biotech was founded in 2001 and is headquartered in Guerande, France, with operations extending to the U.S. market via its Santa Maria, California site. As a private company, it leverages its expertise in lateral flow technology to address critical global health challenges.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance or Authorization for Breakthrough-Designated Rapid Tests70% success
• Q2 2026Clinical Study Results Supporting Test Performance80% success
• Q4 2026Strategic Partnership or Distribution Agreement for U.S. Market Entry60% success